Oncology drug developer Genetron Health, which closed a Vcanbio-led series B round in 2016, has added $61.6m to its coffers.

The partners intend to combine medical device maker LifeTech's expertise in China with ABG's global healthcare investment profile.

KBP Biosciences, which is developing drugs for disease areas of unmet need, raised the series A funds from investors including Ping An Ventures.

Rewind Therapeutics, which is developing therapies for myelin-related diseases like MS, secured $18.3m in a Boehringer Ingelheim and Merck Group-backed round.

Cityblock, a care coordination platform incubated by Alphabet-owned Sidewalk Labs, has raised $20.8m from investors including Sidewalk.

Bristol Myers-Squibb co-led the genomic testing technology provider's series B round, which will support the expansion of its cancer tests to patients.

An oncology team led by Johns Hopkins professor Marikki Laiho has been backed by the commercialisation fund, becoming its first recipient.

The deal was closed following commitments from Nan Fung Life Sciences and Madryn Asset Management, a year after iCarbonX made its anchor investment.